1. Name and Address of Reporting Person

Duncan Barbara Gayle

225 FRANKLIN STREET
SUITE 2100
BOSTON
MA
02110

2. Issuer Name and Ticker or Trading Symbol

Atea Pharmaceuticals, Inc. [ AVIR ]

3. Date of Earliest Transaction (Month/Day/Year)

06/17/2022

5. Relationship of Reporting Person(s) to Issuer

X Director

Officer (give title below)

Other (specify below)

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X Form filed by One Reporting Person

Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>Code</th>
<th>(A)</th>
<th>Amount</th>
<th>(D)</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>61,264</td>
<td>$61,264</td>
<td>06/16/2032</td>
<td>Common Stock</td>
</tr>
</tbody>
</table>

Explanation of Responses:

1. The option vests and becomes exercisable in twelve (12) equal monthly installments following June 17, 2022, such that the option shall be fully vested on the first anniversary of the date of grant, subject to the Reporting Person's continued service through each such vesting date.

Remarks:

/s/ Andrea Corcoran, as Attorney-in-Fact for Barbara Gayle Duncan

06/21/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.


Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.